Breast cancer plasma biopsy by in situ determination of exosomal microRNA-1246 with a molecular beacon

The Analyst ◽  
2021 ◽  
Author(s):  
Yun Chen ◽  
Ling-Yan Zhai ◽  
Li-Min Zhang ◽  
Xiao-Shan Ma ◽  
Zheng Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nucleic Acids ◽  
Molecular Beacon ◽  
Blood Biopsy ◽  
Modified Molecular Beacon ◽  
Exosomal Microrna

A simple and accurate blood biopsy without extracting plasma exosomes and their nucleic acids content was developed using a modified molecular beacon.

A facile deoxyuridine/biotin-modified molecular beacon for simultaneous detection of proteins and nucleic acids via a label-free and background-eliminated fluorescence assay

The Analyst ◽  
2019 ◽  
Vol 144 (18) ◽  
pp. 5504-5510 ◽  
Author(s):  
Fei Yin ◽  
Liqi Liu ◽  
Xia Sun ◽  
Laiyong Hou ◽  
Yu Lu ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Nucleic Acids ◽  
Molecular Beacon ◽  
Simultaneous Detection ◽  
Cancer Biomarkers ◽  
Label Free ◽  
Early Diagnosis Of Cancer ◽  
Different Types ◽  
Diagnosis Of Cancer ◽  
Modified Molecular Beacon

Simultaneous detection of different types of cancer biomarkers (nucleic acids and proteins) could facilitate early diagnosis of cancer and clinical treatment.

scholarly journals Correction: A facile deoxyuridine/biotin-modified molecular beacon for simultaneous detection of proteins and nucleic acids via a label-free and background-eliminated fluorescence assay

The Analyst ◽  
2020 ◽  
Vol 145 (22) ◽  
pp. 7448-7448
Author(s):  
Fei Yin ◽  
Liqi Liu ◽  
Xia Sun ◽  
Laiyong Hou ◽  
Yu Lu ◽  
...  
Keyword(s):  
Nucleic Acids ◽  
Molecular Beacon ◽  
Simultaneous Detection ◽  
Fluorescence Assay ◽  
Label Free ◽  
Modified Molecular Beacon

Correction for ‘A facile deoxyuridine/biotin-modified molecular beacon for simultaneous detection of proteins and nucleic acids via a label-free and background-eliminated fluorescence assay’ by Fei Yin, et al., Analyst, 2019, 144, 5504–5510, DOI: 10.1039/C9AN01016E.

scholarly journals Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer

2013 ◽  
Vol 139 (2) ◽  
pp. 144-150 ◽  
Author(s):  
Aaron S. Mansfield ◽  
William R. Sukov ◽  
Jeanette E. Eckel-Passow ◽  
Yuta Sakai ◽  
Frank J. Walsh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Her2 Status

scholarly journals Human epidermal growth factor receptor 2 testing in breast cancer

2010 ◽  
Vol 63 (1-2) ◽  
pp. 69-74 ◽  
Author(s):  
Tatjana Ivkovic-Kapicl ◽  
Slavica Knezevic-Usaj
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
In Situ Hybridization ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Gene Amplification ◽  
Growth Factor Receptor ◽  
Epidermal Growth

Introduction. Testing for human epidermal growth factor receptor-2 in breast cancer at the time of primary diagnosis is now the standard of care. Positivity for epidermal growth factor receptor-2 in breast cancer is a prognostic factor regarding tumor aggressiveness and a predictive factor for response to Herceptin. Accurate assessment is essential to ensure that all patients who may benefit from Herceptin are correctly identified. Assay method. The principal testing methods used for determination of epider?mal growth factor receptor-2 status are immunohistochemistry for protein over expression and in situ hybridization using either fluorescence or a chromogen. Immunohistochemical testing method allows identification of epidermal growth factor receptor-2 positive patients (3+) who may benefit from Herceptin therapy, whereas negative patients (0/1+) can be excluded. A proportion of specimens defined as equivocal by immunohistochemistry (2+) must be retested by in situ hybridization to determine their status. Chromogen in situ hybridization is a method for determination of gene amplification using a peroxidase-based chromogenic reaction, which can be viewed using a conventional bright field microscope and it determines the actual degree of gene amplification. Various factors can affect the results achieved with these assays, including the assay antibody/probe, the methodology and the experience of personnel. Many countries implemented national testing guidelines in an attempt to standardize testing procedures and make results more accurate. Conclusion. The key point underlined by this review is that whatever method is used to test HER2 status, the technology must be validated first, and there must be regular internal and external quality assurance procedures.

scholarly journals Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

2003 ◽  
Vol 88 (10) ◽  
pp. 1587-1591 ◽  
Author(s):  
L Arnould ◽  
Y Denoux ◽  
G MacGrogan ◽  
F Penault-Llorca ◽  
M Fiche ◽  
...  
Keyword(s):  
Breast Cancer ◽  
In Situ Hybridisation ◽  
Her2 Status
Sign in / Sign up

Export Citation Format

Share Document